UWE supports third of Silicon Gorge Finalists

The Investor Showcase, Silicon Gorge, takes place (virtual this year) on the 29th April. 12 companies will present to an invited audience of investors. 70 start-ups applied for this opportunity, they were initially whittled down to 24, who presented to a panel of start-up experts, who then selected the 12 finalists.

 

Of these 12, 4 are based in either the BRL Hardware Incubator or Future Space. All 4 have received significant support from UWE; help with their business development strategies, fund raising plans, and the pitches that they will be giving on Wednesday.

 

This is a rare opportunity to show how some start-ups (who haven’t had much help from any of the HMRC aid packages) are still being supported by UWE / BRL and are still fighting for a future for when the current situation ends.

 

The four companies are (in alphabetical order):

 

[BRL Hardware Incubator]

Altered Carbon develop graphene-based sensors which can detect a range of chemical compounds. They are working towards creating a chip that uses multiple sensor elements on an array. Their chip is combined with artificial intelligence to help identify unique smells, by digitally fingerprinting them in real-time. They aim to bridge the gap between the physical and digital realm and to allow humankind to know more than ever before.

 

[Future Space]

Ferryx is a recently incorporated University of Bristol spin-out company, which is developing safe, effective bacterial products to prevent and treat gastrointestinal inflammatory illness in humans and animals.

 

[BRL Hardware Incubator]

Neoptera Aero is electrifying the future of Vertical flight by developing the eOpter, an electric Vertical Take-Off and Landing (eVTOL) aircraft that offers a safer, more affordable and more environmentally conscious alternative to helicopters and other forms of vertical flight.

 

[Future Space]

Vitamica is developing a new, rapid method of showing which antibiotic will be most effective to treat a patient’s infection; helping to improve health outcomes, reduce costs and slow the spread of antibiotic resistance